2016 ESC and ACC/AHA/HFSA heart failure guideline update - what is new and why is it important?
Heart failure (HF) is a global epidemic affecting millions of individuals worldwide. Although important progress has been made in the management of HF, this condition remains a common cause of morbidity and death. Since the publication of the previous sets of guidelines for the management of HF, new diagnostic and therapeutic options for HF have emerged. Now, both the ESC and the ACC/AHA/HFSA have simultaneously published an update of their guidelines incorporating, among others, recommendations for the use of new pharmacological therapies for the treatment of HF. For this Viewpoint article, we have asked the chairs of the ESC Task Force, the chairs of the ACC/AHA/HFSA Writing Committee, and an independent opinion leader in the field to offer their expert insight into the new guidelines, highlighting what is new, what the main differences are between the two sets of guidelines, and what steps should be taken to improve the guidelines in future updates.
Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Building 421, Philadelphia, Pennsylvania 19104, USA.
Mariell
M
Jessup
Baker-IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria 3004, Australia.
Thomas H
TH
Marwick
Department of Heart Disease, Wroclaw Medical University, Centre for Heart Diseases, Military Hospital, ul.Weigla 5, 50-981 Wroclaw, Poland.
Piotr
P
Ponikowski
Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, Netherlands.
Adriaan A
AA
Voors
Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University, Feinberg School of Medicine, 676 North St. Clair, Suite 600, Chicago, Illinois 60611, USA.
Clyde W
CW
Yancy
D000572:American Heart Association; D002309:Cardiology / Q000592:standards*; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D032921:Consensus; D019317:Evidence-Based Medicine / Q000592:standards; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards*; D011237:Predictive Value of Tests; D012955:Societies, Medical / Q000592:standards*; D016896:Treatment Outcome; D014481:United States
D002317:Cardiovascular Agents